02161nas a2200229 4500000000100000008004100001260001200042100001400054700001200068700001300080700001100093700001600104700001100120700001000131700001400141245011700155856006300272300001200335490000800347520156200355022001401917 2018 d c11/20181 aChukwu JN1 aEkeke N1 aNWAFOR C1 aMeka A1 aAlphonsus C1 aMbah O1 aEze C1 aUkwaja KN00aWorsening of the disability grade during leprosy treatment: prevalence and its determinants in Southern Nigeria. uhttps://academic.oup.com/trstmh/article/112/11/492/5090840 a492-4990 v1123 a

Background: In Nigeria, little is known about the development of new or additional physical disability during leprosy treatment. The objective of this study was to determine the prevalence and evaluate factors associated with worsening of physical disability during leprosy treatment in Nigeria.

Methods: This was a retrospective cohort study conducted among leprosy patients treated in six referral facilities in six States in Nigeria between January 2011 and December 2015. Multivariable logistic regression analysis was used to identify predictors of worsening disability after treatment.

Results: Of 984 leprosy patients who completed treatment, the mean age of the patients was 39.8±17.6 years and 57.4% (565/984) of them were male. Also, 51.6% (508/984) of the patients had either grade 1 or 2 disability at diagnosis, but this declined to 30.8% (303/984) following treatment (p<0.001). Overall, 4.7% (46/984) of the cases developed new or additional disability (or worsening disability) during treatment. The cases with the greatest odds for developing worsening physical disability were patients from the southwest (adjusted odds ratio [aOR] 15.9; 95% CI 3.8-67.4) and southeast zones (aOR 4.7; 95% CI 1.1-19.2), and patients who had a leprosy reaction requiring additional corticosteroid therapy (aOR 11.7; 95% CI 4.4-31.2).

Conclusion: Sustained capacity building for health professionals on better monitoring and management of leprosy and its complications is strongly recommended in Nigeria.

 a1878-3503